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654Objectives:Reconstruction of the right ventricular outflow tract plays a major role in congenital cardiac surgery.
With the advent of the Contegra bovine jugular vein graft and the Shelhigh pulmonic xenograft, hopes were high
that the lack of availability of homografts would be overcome. The present study evaluated both grafts and
investigated the influence of known risk factors for premature graft failure.
Methods: From December 1999 to September 2008, 84 consecutive patients (mean age, 12  15 years) with
a total of 100 implanted conduits (43 Contegra bovine jugular vein grafts and 57 Shelhigh pulmonic xenografts)
were included in this study. Primary end points were reintervention, reoperation, and death.
Results: The rate of overall conduit replacement was 25% for the Shelhigh pulmonic xenograft versus 26% for
the Contegra bovine jugular vein graft. The predominant mode of failure was conduit stenosis for both groups
(23% for the Shelhigh pulmonic xenograft vs 19% for the Contegra bovine jugular vein graft), with a mean time
to replacement of 18  9 months for the Shelhigh pulmonic xenograft versus 42  4 months for the Contegra
bovine jugular vein graft (P¼ .25). Histopathological analysis revealed a similar chronic inflammatory reaction
in both conduits, but it was significantly stronger in the Shelhigh pulmonic xenograft group. The Contegra bo-
vine jugular vein graft showed frequently the formation of a stenotic membrane at the distal anastomosis site.
Age of less than 1 year, body surface area, pulmonary stenosis, and conduit size of less than 14 mm could not be
identified as risk factors for premature failure.
Conclusions: Both conduits fail predominantly because of stenosis and are subject to a chronic inflammatory
reaction, although this was stronger in the Shelhigh pulmonic xenograft group. Mean time to replacement
was 18  9 months for the Shelhigh pulmonic graft group versus 42  4 months for the Contegra bovine graft
group (P ¼ .25). Because there is a trend toward earlier failure in the Shelhigh pulmonic xenograft group, we
currently prefer to implant the Contegra bovine jugular vein graft for right ventricular outflow tract reconstruc-
tion. (J Thorac Cardiovasc Surg 2011;141:654-61)Reconstruction of the right ventricular outflow tract
(RVOT) plays an important role in congenital cardiac
surgery. The advances in correcting complex congenital
cardiac malformations created an increasing demand for
right ventricle (RV)–pulmonary artery (PA) conduits. Espe-
cially for small sizes, the availability of homografts is lim-
ited. With the advent of the Contegra bovine jugular vein
graft (CBG; Medtronic, Inc, Minneapolis, Minn) and the
second-generation Shelhigh pulmonic xenograft (SPG;
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The Journal of Thoracic and Cardiovascular Surgthis lack could be overcome. After initial promising results
for both grafts,1-3 reports regarding unexpected early failure
in the CBG,4 as well as the SPG,5 dampened the optimism.
Several studies were published reporting early and midterm
results for either conduit and showed the failure of the grafts
because of stenosis at the distal anastomosis or marked an-
eurysmal dilation with the CBG or excessive neointimal
proliferation with the SPG. In our initial experience the
CBG showed good hemodynamic performance, but after
a mean follow-up of 18 months, 16% of the grafts had to
be replaced.6,7 Immunogenic properties of the graft
material leading to excessive intimal peel and perigraft
scarring, as well as risk factors, such as small conduit size
and the presence of pulmonary stenosis (PS), or technical
aspects of implantation, were frequently discussed to be
responsible for early conduit failure. However, until the
present, the diversity of the findings of published studies
could not clearly identify reasons for the observed
differences in graft durability and mode of failure. Neither
was it possible to demonstrate advantages of one type of
conduit over the other. Thus far, there is no report ofery c March 2011
Abbreviations and Acronyms
CBG ¼ Contegra bovine jugular vein graft
CRP ¼ C-reactive protein
DORV ¼ double-outlet right ventricle
PA ¼ pulmonary artery
PS ¼ pulmonary stenosis
RV ¼ right ventricle
RVOT ¼ right ventricular outflow tract
SPG ¼ Shelhigh pulmonic xenograft
TGA ¼ transposition of the great arteries
VSD ¼ ventricular septal defect
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Dsimultaneous experience with both conduit types, and to the
best of our knowledge, no randomized controlled trials have
been conducted. The present study reports a single-center
experience with the 2 xenograft RVOT conduits, the CBG
and the second-generation SPG, for RVOT reconstruction
from December 1999 to September 2008 in a constant sur-
gical environment.
Up to now, young age of the patient (<1 year), small con-
duit size (<14 mm), and presence of PS are considered risk
factors in determining graft durability. The present study in-
vestigates the influence of these characteristics on conduit
durability.MATERIALS AND METHODS
From December 1999 to September 2008, 84 consecutive patients
(mean age, 12  15 years) with a total of 100 implanted conduits (43
with the CBG and 57 with the SPG) were included in the present study.
RVOT reconstruction became necessary because of various congenital car-
diac defects, comprising both patients with primary procedures and those
with reoperations. Choice of conduit was primarily based on availability
and can be divided into 3 phases. With its introduction in 1999, we started
primarily implanting the Contegra graft (phase 1) until reports of early fail-
ure and the advent of the second-generation Shelhigh graft. After a year of
overlap (2003), we continued with the Shelhigh graft (phase 2) from 2004
until early 2007, when, after unexpected failure in several pediatric but also
adult patients, we abandoned the use of all Shelhigh products. Since then,
the CBG has been our preferred conduit (phase 3). During the study period,
we implanted 15 homografts, mainly in patients with endocarditis or older
patients undergoing RVOT replacement in whom either of the other grafts
had failed more than once. Primary end points were reintervention, reoper-
ation, and death. An RV–PA gradient of greater than 50 mm Hg was con-
sidered to be a significant conduit stenosis. Follow-up was performed by
means of echocardiographic analysis or magnetic resonance imaging as ap-
propriate at 0, 3, 6, and 12 months after surgical intervention and then once
a year, depending on the findings. All other techniques of RVOT recon-
struction (transanular patch, monocusp xenograft, and homograft) are
excluded from this report.
Surgical Technique
Techniques for RVOT reconstruction remained constant during the
study period. We only used non–ring-enforced CBGs, as well as second-
generation SPGs with a bovine pericardial tube graft instead of a porcine
PA as in the first generation. The conduits were treated according to theThe Journal of Thoracic and Caspecifications of the manufacturer. For the CBG, 3 sterile bowls containing
500mL of physiological electrolyte solution were prepared for rinsing. The
graft was taken out of the jar with atraumatic forceps, and residual storage
solution was drained. After the graft was rinsed 3 times for 5 minutes in the
3 bowls containing the physiological electrolyte solution and left in the last
bowl until needed for implantation. In contrast to the CBG, a rinsing pro-
cedure is not required by the handling instructions of the manufacturer for
the SPG but could be performed, if wished, by rising it in 500 mL of saline
solution for at least 2 minutes. Thus the SPGs were rinsed in 500 mL of sa-
line solution for 2 to 3 minutes before implantation. Both conduits were al-
ways implanted with the valve as distal as possible. In case of redo surgical
intervention, residual conduit material was completely removed. The
‘‘hood’’ of the proximal anastomosis was performed without additional
prosthetic material, whereas bovine pericardial patches were used when
augmentation of the PAs became necessary. The distal anastomosis was
performed in an end-to-side fashion by using a continuous polypropylene
suture if no stenosis of the PA was present. If the anastomosis includes
the bifurcation itself or a stenosis is present, the PA is incised, and
a more elliptical anastomosis is created to allow for a harmonious transi-
tion. Surgical intervention was performed by using all levels of extracorpo-
real support from deep hypothermic circulatory arrest to moderate
hypothermia and beating heart surgery.
Data Collection
Data were collected in a prospective fashion according to European
Cardiac Surgery Registry criteria. Furthermore, a special database for
patients with RVOT conduits was initiated. The study was approved by
the institutional review committee, and informed consent was obtained.
Statistical Analysis
Data analysis was performed by a statistician (BG) unaware of the clin-
ical situation and outcome. In addition to descriptive statistics, data under-
went a Kaplan–Meier survival analysis, with explantation caused by
stenosis as an event, followed by a log rank test to compare the event
risk for the 2 types of conduits. A Cox regression analysis to identify inde-
pendent risk factors for graft failure, such as age, conduit size, and PA ste-
nosis, was calculated. Analysis was performed with SPSS version 15.0
software (SPSS, Inc, Chicago, Ill).RESULTS
Surgical intervention was performed in 84 patients, im-
planting 100 conduits because of tetralogy of Fallot
(n ¼ 46), pulmonary atresia (n ¼ 3), isolated PS (n ¼ 4),
double-outlet right ventricle (DORV)/PS (n ¼ 3), DORV/
transposition of the great arteries (TGA; n ¼ 3), TGA/ven-
tricular septal defect (VSD)/PS (n ¼ 7), truncus arteriosus
communis (n ¼ 4), pulmonary insufficiency (n ¼ 1), and
Ross procedures (n ¼ 13). Overall follow-up was 100%
complete, with an average time of 45.5  29.4 months. Be-
cause of market introduction and availability, there was
a significant difference in follow-up time (P ¼ .02) for
the 2 grafts, with an average of 57  40 months in the
CBG group and 37  12 months in the SPG group. The
mean age in the CBG group was 4.5  5.5 years versus
18  17.6 years in the SPG group (P<.0001). Comparison
of both groups showed that children less than 1 year of age
were more prevalent in the CBG group (33% [n ¼ 14] vs
16% [n ¼ 9]) than in the SPG group, although this did
not reach statistical significance (P ¼ .06). Mean bodyrdiovascular Surgery c Volume 141, Number 3 655
FIGURE 1. Kaplan–Meier curve for freedom from explantation for Shel-
high pulmonic xenografts (gray line) and Contegra bovine jugular vein
grafts (black line). Patients at risk are shown for both groups in correspond-
ing numbers in brackets. The dashed line marks the performance of both
conduits at 24 months.
FIGURE 2. Scatter plot for time to explantation in the Shelhigh pulmonic
xenograft and Contegra bovine jugular vein graft groups. A trend toward
a shorter time span to explantation is demonstrated for the Shelhigh
pulmonic xenograft group.
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(P< .0001), and mean conduit size was 16 mm in the
CBG group versus 20 mm in the SPG group (P<.0001).
The presence of PS was equally distributed between groups
(84% vs 79%, P ¼ .61).
The rate of reintervention was equal in both groups (2%
[n¼ 1] in the SPG group vs 2% [n¼ 1] in the CBG group).
Because reinterventions by means of balloon dilatation
were not successful, these patients consecutively underwent
reoperation.
The overall rate of replacement was 26% (n ¼ 11) in the
CBG group and 25% (n ¼ 14) in the SPG group. Reopera-
tion caused by stenosis became necessary in 19% (n¼ 8) in
the CBG group and 23% (n ¼ 13) of the SPG group
(P¼ .14, Figure 1). The RV–PA maximal pressure gradient
value before redo surgical intervention was 69 29 mmHg
in the CBG group versus 76  28 mm Hg in the SPG group
(P ¼ .6). Other reasons for conduit exchange included sus-
pected endocarditis in 7% (n ¼ 3) of the CBG group and
1.8% (n ¼ 1) of the SPG group, respectively. Replacement
because of stenosis within the first 2 years was performed in
9% (n ¼ 4 of a total of 8 stenotic CBGs) of patients in the
CBG group and in 18% (n ¼ 10 of a total of 13 stenotic
SPGs) of patients in the SPG group (P ¼ .38). The mean
time to replacement because of conduit stenosis was found
to be 42  35 months in the CBP group versus 18  9
months in the SPG group (P ¼ .25, calculated with a log
rank test on the basis of the Kaplan–Meier survival model,
thus taking into account the risk for explantation rather than656 The Journal of Thoracic and Cardiovascular Surgthe time of explantation), and even though not significant,
a trend toward earlier explantation was found for SPGs
(Figure 2).
Regarding perioperative parameters, a significant differ-
ence for C-reactive protein (CRP) values was found be-
tween the 2 groups. Patients receiving a SPG showed
a significantly higher mean increase (100  79 mg/L,
P ¼ .001), as well as a higher maximum level (114  88
mg/L, P<.0001), of CRP compared with that seen in pa-
tients receiving a CBG (mean increase, 46 49 mg/L; max-
imal level, 48  49 mg/L). Patients with a confirmed
bacterial or viral infection were excluded. In the SPG group
75% of patients received aspirin immediately postopera-
tively, whereas this was only the case in 26% of patients
in the CBG group; oral anticoagulation was initiated in
9% of the SPG group and 5% of the CBG group.
Explanted conduits were sent to pathology for histologi-
cal and immunohistochemical analysis, which revealed
a chronic inflammation with foreign body reaction and lym-
phocyte infiltration for both conduits (Figure 3). The SPGs
showed a severely thickened and fibrotic conduit wall,
which was more pronounced than in the CBGs. In both
conduits the valve leaflets were mostly found to be intact,
pliable, and without infiltration. In contrast to the SPGs,
in which the formation of a thickened and fibrotic conduit
wall narrowed the internal lumen of the graft over its full
length, the CBGs demonstrated deposition of a fibrous, pau-
cicellular tissue and fibrin deposition on its luminal aspect,
although with a narrowing of the distal lumen of the graft by
the formation of a fibrotic membrane. For both grafts,ery c March 2011
FIGURE 3. Histopathology of explanted Shelhigh pulmonic xenograft and Contegra bovine jugular vein graft conduits. A, Explanted longitudinally
opened Shelhigh pulmonic xenograft showing a thickened and fibrotic conduit wall with thin and pliable valve leaflets. B, Hematoxylin and eosin staining
of a Shelhigh pulmonic xenograft and overview of the graft material. The partially destructed graft material (SG) is surrounded by granulation tissue, with
accumulation of macrophages and lymphocytes and numerous foreign body multinuclear giant cells. The luminal aspect (#) reveals substantial fibrosis and
focally paucicellular scar tissue. The adventitial aspect (*) shows formation of a wide neoadventitia penetrated by strong inflammatory infiltrate. The black
arrow denotes suture material in situ. C, Hematoxylin and eosin staining of a Shelhigh pulmonic xenograft revealing a partially destructed graft material.
Florid granulation tissue takes up much of the image (*), bordered in part by paucicellular scar tissue. The predominantly macrophage- and lymphocyte-rich
inflammatory infiltrate also reveals numerous foreign body multinucleate giant cells (black arrows). These giant cells are in part found surrounding suture
material but are also located along the outer aspect of the graft boundaries, as well as in the vicinity of largely degraded collagenous graft fibers. Grouped
microcalcifications (white arrows) are occasionally located within the graft wall. D, Masson trichrome staining of a Shelhigh pulmonic xenograft with over-
view of the graft from the inner luminal aspect with the attached valve leaflet (left) to the adventitial aspect (right). The valve leaflet is essentially intact and
delicate, without significant inflammatory infiltrate or fibrosis. The luminal aspect is characterized by a fibrous paucicellular tissue and fibrin deposition
delineated by a mixed inflammatory infiltrate. E, An explanted longitudinally opened Contegra bovine jugular vein graft revealing a fibrotic membrane
formation at the site of the distal anastomosis. The Contegra bovine jugular vein graft leaflets appear intact, thin, and pliable. F, Hematoxylin and eosin
staining of a Contegra bovine jugular vein graft showing a continuous fibrin deposition on the intimal aspect (upper side of the specimen). The whole graft
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tructed graft material with degraded collagen fibers, which
was surrounded by florid granulation and scar tissue with
accumulation of macrophages, lymphocytes, and numerous
foreign body multinuclear giant cells. The luminal aspect
reveals substantial fibrosis and focally paucicellular scar
tissue. The adventitial aspect shows formation of a wide
neoadventitia penetrated by strong inflammatory infiltrate.
Focal microcalcifications were observed within both
conduit walls.
Overall hospital and long-term mortality was 8% (n¼ 3)
in the CBG group versus 4% (n ¼ 2) in the SPG group. Of
the 3 patients in the CBG group, one child died of acute
right heart failure during anesthesia induction before reop-
eration for conduit exchange. The second child died after
correction of DORV with complete pulmonary atresia and
VSD after unsuccessful weaning from postcardiotomy ex-
tracorporeal membrane oxygenation support. The third
child underwent corrective surgical intervention for com-
plex TGA with inlet VSD and hypoplastic aortic valve.
The child experienced severe respiratory failure and died
on postoperative day 2 on extracorporeal membrane oxy-
genation support. In the SPG group 1 child died of unclear
reasons, most probably arrhythmia, several months postop-
eratively after correction of aortic stenosis by means of
a Ross procedure. Autopsy was performed and showed an
unremarkable situs. The second child in the SPG group
died of postoperative circulatory failure after a complex
fourth reoperation with conduit exchange for correction of
a DORV.
Regression Analysis
A Cox regression analysis was performed regarding the
expected influence factors of age, presence of PS, and con-
duit size for premature conduit failure. Conduit type was
also included in the analysis. This did not lead to a predic-
tion model of the hazard ratio for conduit failure. Surpris-
ingly, of all possible influence factors, conduit type was
the closest to reaching significance (P ¼ .06), whereas the
other factors were far off: age less than 1 year (P ¼ .48),
body surface area (P ¼ .96), presence of PS (P ¼ .51),
and conduit size less than 14 mm (P ¼ .24). Given the dif-is penetrated by a strong inflammatory infiltrate with macrophage and lymphocy
but is most prominent within the adventitia, as well as on the internal luminal as
lagen fibers are partially destructed. G,Masson trichrome staining, with an overv
the site of anastomosis to the pulmonary artery. The inner lumen (*) is substanti
inner aspect with a thin pseudointima largely devoid of an endothelial lining. T
scribed areas of fibrin deposits (__) between the inner fibrous ring and outer asp
between the pulmonary artery and Contegra graft. The rectangle denotes the are
(white arrow) between the pulmonary artery (*) and Contegra bovine jugular v
from suture material removed in the process of sample preparation. The arrow
bordering the Contegra bovine jugular vein graft material. The elastic lamellae
and collagenous scar tissue are apparent in this area.
:
658 The Journal of Thoracic and Cardiovascular Surgferent odds ratios of conduit type, one could see a trend
toward better performance in the CBG group by reduction
of the probability of explantation by 60%. However, it
has to be taken into consideration that this is based on an
overall nonsignificant prediction model.Limitations
Because the conduits did not appear simultaneously on
the European market, this results in an unequal follow-up.
Additionally, selection of the conduits was biased by the
availability of the conduit and the choice of the surgeon
during phase 2 of the study.DISCUSSION
Homografts present the benchmark for RVOT conduit
performance, with an approximate 10-year freedom from
reoperation of 60% to 90%.8,9 The most common mode
of premature failure for homografts is early calcification
and valve insufficiency, especially in patients with
increased PA pressure. Freedom from reoperation varies
according to the patient population. Age and conduit size
have been determined as independent risk factors for
freedom from reoperation. Immunologic factors, such as
blood group incompatibility, are also discussed to
influence homograft durability because several reports
have shown better results when using matched
homografts.10,11
Comparing conduit performance is difficult. A definitive
statement about conduit performance would require a pa-
tient population with the same defects in the same age group
and equally distributed primary procedures and reopera-
tions. A conduit used to replace the pulmonary valve in
a Ross procedure will perform differently from an RVOT
conduit in the setting of a hypoplastic PA with severe pul-
monary hypertension. Furthermore, it can be difficult to dis-
tinguish between real premature conduit failure and failure
caused by normal somatic outgrowth. Especially in small
conduit sizes (10 or 12 mm), a very large patient cohort
would be required to demonstrate a significant difference
and at the same time eliminate the bias of somatic out-
growth.te accumulation and giant cell reaction. Infiltration is observed in all layers
pect of the graft. The media reveal tears and focal microcalcifications. Col-
iew of a transverse section through the Contegra bovine jugular vein graft at
ally narrowed by a fibrous membrane (**). The graft itself is covered on the
he adventitial aspect (***) reveals focal thickening and fibrosis. Circum-
ects of the graft wall are shown. Arrows denote the points of anastomosis
a shown enlarged in panel H. H, Enlarged image of the point of anastomosis
ein graft (#). Black arrows point to artificial lumina representing channels
head reveals an area of palisading foreign body multinucleate giant cells
of the pulmonary artery are partially loosened, and fibroblast infiltration
ery c March 2011
TABLE 1. Literature overview of CBG and SPG studies
Author
Year of
publication
SPG,1;
CBG, 2
No. of
patients
Conduits
(n)
Mean age
(y)
Ross
procedure (%)
Redo
operations (%)
Mean
follow-up
Explantation
(%)
Reintervention
(%)
Marianeschi et al12 2001 1 25 25 20.2 68 32 30 8 0
Ishizaka et al5 2003 1 24 25 2.8 0 NA 23 48 8
Schreiber et al13 2006 1 34 34 0.6 0 27 12 44 0
Kim et al14 2007 1 73 81 6.8 4 NA 11 12.3 0
Carrel et al6 2002 2 21 22 0 4.5 9.1
Corno et al22 2002 2 26 26 13.5 42 NA 15 0 0
Bove et al21 2002 2 41 41 1.9 12 20 NA 0 0
Breymann et al15 2004 2 104 108 4.3 1 69 25 8 NA
Corno et al1 2004 2 67 67 16.1 40 58* 26 1.5 7.5
Meyns et al20 2004 2 57 58 9 17 53 23 12 29
Tiete et al17 2004 2 29 29 3.4 0 41 10 3.4 6.9
Goeber et al7 2005 2 36 38 2.1 0 NA 18 16 0
Brown et al16 2006 2 62 62 7.3 6 63 26 1.6 11.3
Rastan et al23 2006 2 78 78 12.9 NA 72 31 12.8 24.4
Shebani et al19 2006 2 62 64 1.2 0 19.4 14 6.3 9.4
Sierra et al24 2007 2 50 50 4.9 0 24 28 4 0
Sekarski et al18 2007 2 133 133 2.6 15 NA 32 9 9
CBG, Contegra bovine jugular vein graft; NA, not applicable; SPG, Shelhigh pulmonic xenograft. *Including interventional procedures.
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and SPGs, let alone a randomized controlled trial. Four big-
ger studies have thus far provided original data on the
follow-up of the SPG (Table 1).1,5,6,7,12-24 Marianeshi and
colleagues12 published the first results on SPGs, mainly
based on patients undergoing a Ross procedure with a me-
dian age of 20.2 years. The SPGs performed well in this
patient population and promised to be an alternative to
homografts. In 2003, Ishizaka and associates5 and in 2006
Schreiber and coworkers13 published their results in a pedi-
atric population. Ishizaka and associates5 reported 25 pa-
tients with a mean age of 2.8  3.9 years. After a mean
follow-up of 23  5 months, 48% of conduits had to be
replaced, and the group abandoned the use of the SPG.
Schreiber and coworkers13 operated on 34 patients with
a mean age of 7 months and had to replace 15 conduits after
medium follow-up of 1 year. Kim and associates14 reported
a freedom from reoperation of only 33.3% within the first
12 months in small conduits but an overall rate of freedom
from reoperation of 87% after 24 months.
In our present study, with a wide span of age and a broad
spectrum of defects, the SPG performs better than in the in-
fant population described by Schreiber and coworkers.13
The graft had to be replaced because of stenosis in 18%
of the patients after 2 years and in 25% after a follow-up
of 37 12 months. Nevertheless, the mean time to replace-
ment in the SPG group was short at only 18  9 months. In
contrast to the study by Kim and associates,14 conduit size
was not an independent risk factor for reoperation.
The literature regarding the CBG is much more diverse
(Table 1). The initial results after the CBG was introduced
to the European market in 1998 within the setting of clinicalThe Journal of Thoracic and Castudies were very encouraging. Breymann and colleagues15
reported 71 patients with a low median age of 1.2 years.
During a mean 27-month follow-up, no conduit failure
was observed. All reoperations in this series were reported
to be not conduit related. Brown and coworkers16 published
results on 62 patients, including 39 with a failed pulmonary
homograft. Mean time to reoperation was 11  8 months,
with 1 conduit replacement and 7 patients undergoing per-
cutaneous intervention. In parallel, reports of conduit fail-
ure because of aneurysmal dilatation, thrombosis, and
early stenosis were published.4,7,17,25,26 In contrast to the
good to excellent results (ie, zero conduit failure, as
reported by Breymann and colleagues15), the mean time
to replacement of CBG conduits in our population was 42
 35 months during an average follow-up of 57  40
months among our CBG patient group. The mean age of
the patients was 4.5  5.5 years. The difference among
the results for the durability of the CBG, as observed by
us and others, is still a matter of ongoing discussion. Con-
sistent with contemporary reports, the predominant mode
of failure was progressive stenosis of the graft with frequent
formation of a stenotic membrane at the distal anastomosis
sometimes associated with aneurysmal dilatation. We did
not observe any valve insufficiency leading to replacement.
In a large series of 133 pediatric patients with a median age
of 31 months, Sekarksi and coworkers18 had to explant 13
conduits, 4 because of problems with the distal anastomo-
sis, 3 because of endocarditis, 1 because of thrombosis,
and 5 during reoperation for distal PA stenosis reported as
being unrelated to the graft. Several studies reported early
failure and aneurysmatic dilatations of the CBGs to be asso-
ciated with increased RV–PA pressures.19,26 Other than 2rdiovascular Surgery c Volume 141, Number 3 659
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by very severe stenosis of the distal anastomosis, this
study could not determine PS as an independent risk
factor for early graft failure.
Several explanations have been given for the repeatedly
observed mode of failure of the CBGs caused by the forma-
tion of the fibrotic membrane at the distal anastomotic site.
A contributing factor might be the proper rinsing of the
Contegra graft. It has been suggested that trimming the dis-
tal part of the graft only after rinsing could lead to residual
glutaraldehyde in the distal suture line and might promote
stenosis.20 An additional technical aspect leading to fibrotic
deposition and membrane formation presents the incorpora-
tion of adventitial tissue into the internal surface of the con-
duit–PA anastomosis. We are not aware of implanting the
graft in such a fashion, and the distal anastomoses were
performed by using a standard end-to-side technique with
a continuous Prolene (Ethicon, Inc, Somerville, NJ) suture
line.
Given our histopathological findings, immunologic
mechanisms appear to be more likely to be responsible
for the early failure of CBG and SPG conduits. Both
types of xenografts show a strong chronic inflammation,
with foreign body reaction and lymphocytic infiltration.
In contrast to the CBG, SBGs demonstrate a thickened
and more fibrotic conduit wall that involves the whole
graft, whereas the stenosis was predominantly located at
the distal anastomosis in the CBGs. Such rather strong
immunologic reactions are not reported for explanted
homografts, even blood group–incompatible homograft
implants.
Our observations are supported by other reports.20,27
Wojtalik and associates28 demonstrated a B-cell increase
of up to 150% of the normal value with T-lymphocyte acti-
vation and the presence of CD69þand CD71þcells after im-
plantation of a CBG at 3 to 6 months postoperatively. The
difference in the intensity of the immunologic reaction,
with a macroscopically stronger fibrosis and thickening of
the SPG throughout the whole conduit and a higher level
of lymphocytic infiltration in all layers of the SPG com-
pared with that seen in CBGs, correlates well with the
observed higher frequency of postoperative fever and max-
imum and mean levels of CRP in the SPG group. Given
these findings and reports of adverse events associated
with other Shelhigh products, our group has stopped
implanting Shelhigh-manufactured grafts.29
Although the influence on graft durability is unclear, as-
pirin is frequently given postoperatively to improve graft
durability. Most authors recommend aspirin for at least 3
months (3, 5, or 10 mg kg1 d1),15 but there are no studies
regarding the direct influence on graft survival. In our study
aspirin could not be determined as an independent factor to
reduce the incidence of stenosis, but this might be due to the
initially inconsistent regimen of postoperative aspirin ther-660 The Journal of Thoracic and Cardiovascular Surgapy in the absence of evidence and guidelines and to a cer-
tain extent due to the concerns of our cardiologists
regarding Reye syndrome. Currently, all patients receive
aspirin postoperatively at a dosage of 10 mg kg1 d1.SUMMARYAND CONCLUSIONS
In the present study both xenograft conduits fail predom-
inantly because of stenosis (23% for SPGs vs 19% for
CBGs), with a mean time to replacement of 18  9 months
for the SPG versus 42  4 months for the CBG (P ¼ .25).
The SPG shows a trend toward earlier explantation, with al-
most three fourths of the SPGs requiring replacement dur-
ing the first 2 years. Cox regression analysis revealed the
reduction of explantation probability by 60% by CBGs
compared with SPGs and did not identify age of less than
1 year, body surface area, PS, and conduit size of less
than 14 mm as risk factors for premature failure.
Histologic analysis demonstrated the formation of a thick
fibrotic wall throughout thewhole conduit in SPGs, whereas
CBGs are frequently found to fail because of the formation
of a stenotic membrane around the distal anastomotic site.
A similar chronic inflammatory reaction was observed in
both conduits after implantation; however, it appears that
there is a stronger reaction in the SPG. Thus immunologic
factors appear to be responsible for graft failure rather
than technical aspects or patients’ characteristics.
Given these findings, our current strategy is to implant
pulmonary homografts in adult patients and to implant
CBGs for the reconstruction of small-sized RVOTs in
children when homografts are not available.
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